Case Study
How NovaBiopharma Reduced CSV Cycle Time by 68% and Achieved Inspection Readiness in 6 Weeks
A mid-size biopharmaceutical manufacturer replaced 400+ hours of manual validation documentation with KarmaSatya's AI-powered platform — passing an FDA pre-approval inspection with zero critical findings.
Company
NovaBiopharma
Industry
Biopharmaceutical Manufacturing
Size
Mid-size (1,200 employees)
Location
New Jersey, USA
Systems Validated
12 GxP-critical computer systems
Regulation
FDA 21 CFR Part 11, GAMP 5 Category 4 & 5
Executive Summary
NovaBiopharma, a mid-size biopharmaceutical manufacturer based in New Jersey, faced a critical compliance deadline: an FDA pre-approval inspection for a new oncology drug candidate was scheduled within 90 days. Their validation team of six was managing 12 GxP-critical computer systems using spreadsheets, shared drives, and manually authored Word documents — a process that had accumulated significant technical debt and traceability gaps.
After deploying KarmaSatya's AI-powered Computer System Validation platform, NovaBiopharma completed IQ/OQ/PQ documentation for all 12 systems in under six weeks, passed the FDA pre-approval inspection with zero critical findings, and permanently reduced their ongoing CSV cycle time by 68%.
The Challenge
Manual Validation at Scale Was Unsustainable
NovaBiopharma's validation team was spending an average of 34 hours per system on documentation alone — drafting User Requirements Specifications, Installation Qualification, Operational Qualification, and Performance Qualification protocols from scratch for each new or updated system. With 12 systems requiring re-validation or initial validation ahead of the inspection, the team faced an impossible workload.
Compounding the time pressure were three systemic issues that had accumulated over years of manual processes.
Traceability Gaps
Requirements were not consistently linked to test scripts, leaving audit trails incomplete and exposing the organisation to 483 observations.
Version Control Chaos
Validation documents existed in multiple versions across shared drives, with no single source of truth. Reviewers frequently worked from outdated drafts.
No Standardised Templates
Each validation engineer authored documents independently, resulting in inconsistent structure, missing mandatory sections, and variable quality across the portfolio.
Audit Preparation Burden
Preparing a complete validation package for a single system took 3–5 days of manual collation, cross-referencing, and gap remediation.
“We had six weeks and twelve systems. With our existing process, that was mathematically impossible. We needed a fundamentally different approach.”
The Solution
KarmaSatya's Four-Phase AI Validation Framework
KarmaSatya deployed its end-to-end CSV automation platform across NovaBiopharma's 12 GxP systems in a structured four-phase engagement aligned to GAMP 5 methodology.
Assess
KarmaSatya's AI engine ingested NovaBiopharma's existing system inventory, vendor documentation, and legacy validation artefacts. It automatically classified each system by GAMP 5 category, identified traceability gaps, and generated a prioritised remediation roadmap.
Configure
The platform was configured to NovaBiopharma's SOPs, regulatory context (FDA 21 CFR Part 11), and internal naming conventions. Risk-based test coverage thresholds were set per system category, and approval workflows were mapped to the existing organisational hierarchy.
Validate
KarmaSatya auto-generated complete IQ/OQ/PQ protocol suites for all 12 systems, with full bidirectional traceability from User Requirements Specifications through to executed test evidence. The validation team reviewed, executed, and approved documentation within the platform — eliminating version control issues entirely.
Certify
The platform compiled inspection-ready validation packages for each system, including complete audit trails, electronic signature records compliant with 21 CFR Part 11, and a master validation summary report. The packages were delivered in FDA-preferred format, ready for immediate submission.
Outcomes
Quantified Results Across Time, Risk, and Readiness
Reduction in CSV cycle time per system (from 34 hours to 11 hours average)
Reduction in audit preparation time (from 3–5 days to less than 1 day per system)
Traceability coverage across all 12 systems — zero gaps identified at inspection
Critical or major FDA 483 observations issued during the pre-approval inspection
Time from platform deployment to full inspection readiness for 12 GxP systems
Estimated cost avoidance from accelerated drug approval timeline and avoided remediation spend
“KarmaSatya didn't just help us pass the inspection — it transformed how we think about validation. We now have a living, auditable system rather than a filing cabinet of static documents.”
NEW YORK, October 8, 2026 /PRNewswire/ —
KarmaSatya, the AI-powered Computer System Validation and regulatory compliance platform purpose-built for life sciences organisations, today published a case study detailing how NovaBiopharma, a mid-size biopharmaceutical manufacturer, achieved full FDA pre-approval inspection readiness across 12 GxP-critical computer systems in six weeks — passing with zero critical findings.
The engagement, which took place ahead of an FDA pre-approval inspection for a new oncology drug candidate, demonstrated a 68% reduction in CSV cycle time, a 74% reduction in audit preparation burden, and 100% traceability coverage across all validated systems. The estimated cost avoidance from the accelerated approval timeline and avoided remediation spend exceeded £2.1 million.
"Life sciences organisations face an impossible tension between the rigour required for regulatory compliance and the speed demanded by competitive drug development timelines," said the KarmaSatya founding team. "This case study demonstrates that AI-powered validation automation resolves that tension — not by cutting corners, but by eliminating the manual inefficiencies that have historically made compliance slow and expensive."
KarmaSatya's platform is aligned to GAMP 5 methodology and supports FDA 21 CFR Part 11 and EU Annex 11 requirements. It delivers end-to-end CSV automation across the Assess, Configure, Validate, and Certify phases, generating inspection-ready IQ/OQ/PQ documentation with full bidirectional traceability and electronic signature compliance.
About KarmaSatya
About KarmaSatya: KarmaSatya is an AI-powered Computer System Validation and regulatory compliance platform designed for pharmaceutical, biotechnology, and medical device organisations. The platform automates the generation of inspection-ready validation documentation — including IQ/OQ/PQ protocols, traceability matrices, and audit-ready packages — aligned to FDA 21 CFR Part 11, EU Annex 11, and GAMP 5. For more information, visit karmasatya.com.
Media Contact
See What KarmaSatya Can Do for Your Validation Programme
Request a personalised demo and discover how quickly your team can achieve inspection readiness.